Exclusivity for the last valid Ampyra patent expires today, Cantor Fitzgerald analyst William Tanner tells investors in a research note. The analyst points out that four other Orange Book-listed patents were ruled invalid by a District Court in 2017. Shares of Acorda Therapeutics are down 17% since the company disclosed on July 25 that a U.S. Court of Appeals denied a motion for an injunction pending its appeal of that decision, Tanner writes. He notes that exclusivity expiration of the last valid patent coupled with the injunction denial means that generic fampridine developers could launch their versions. The analyst reiterates a Neutral rating on Acorda with a $17 price target.